CD8A and neoplasm: Tumors with MUC16 mutations exhibit heightened immunogenicity, reflected by an increased proportion of CD8A and Programmed cell death 1 ligand 1 (PD-L1)-positive cells in the tumor microenvironment compared to wild-type tumors.